I dumped my few shares of Celgene this morning after it took down forward guidance and reported problems with new drugs — like its Crohn’s disease drug. Down 18%+ this morning, Celgene is probably a bargain. But I’ve had gambling with biotech and pharma companies. There’s no way to predict which cures will work and […]